Affordable Semaglutide Arrives
The landscape of semaglutide accessibility in India has dramatically changed following the expiration of its patent. Previously, patients faced substantial
monthly costs, with branded formulations from international manufacturers ranging from ₹8,000 to ₹12,000, contingent on dosage and form. This high price point often limited access for many. However, the introduction of generic versions by domestic pharmaceutical companies is poised to revolutionize this scenario. In the initial stages, these locally produced alternatives are anticipated to bring down the cost by a considerable 30% to 60%. This significant price reduction is expected to open the doors for a much larger segment of the population to benefit from the therapeutic advantages of semaglutide, addressing conditions that were previously financially out of reach for many individuals.
Quality and Misuse Warnings
While the advent of more affordable generic semaglutide is a welcome development for patient access, it also brings forth critical concerns from the medical community. Endocrinologists and medical bodies are highlighting the potential for misuse and the risks associated with varying quality standards. Dr. K.V.S. Hari Kumar, an endocrinologist and secretary of the Endocrine Society of India, notes that the market is likely to consolidate over the next one to two years. He predicts that only manufacturers capable of upholding stringent production and quality control measures will persist. This suggests a period of flux where less rigorous producers might exit the market. The emphasis is on ensuring that the efficacy and safety of these generic drugs are on par with their branded predecessors, preventing any compromise in patient care due to cost-cutting measures that might impact quality.
